Cardiovascular case fatality in rheumatoid arthritis is decreasing; First prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Meek, Inger L ^a,b   Vonkeman, Harald E ^a   Van De Laar, Mart Afj ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular risk; Mortality; Rheumatoid arthritis

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ADULT; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DRUG USE; FATALITY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SMOKING; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; DISEASE COURSE; MIDDLE AGED; MORTALITY; RISK FACTOR; CARDIOVASCULAR MORTALITY; DISEASE ACTIVITY SCORE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; THORAX PAIN;

AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84902246259     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-142     Document Type: Article

References (37)

1. Mortality among arthritics. Monson RR, Hall AP, J Chronic Dis 1976 29 459 467 10.1016/0021-9681(76)90086-2 939801
2. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP, Arthritis Rheum 2002 46 2010 2019 10.1002/art.10419 12209502
3. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Goodson N, Marks J, Lunt M, Symmons D, Ann Rheum Dis 2005 64 1595 1601 10.1136/ard.2004.034777 15843450
4. The widening mortality gap between rheumatoid arthritis patients and the general population. Gonzalez A, Maradit KH, Crowson CS, Nicola PJ, Davis JM III, Therneau TM, Roger VL, Gabriel SE, Arthritis Rheum 2007 56 3583 3587 10.1002/art.22979 17968923
5. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D, Arthritis Rheum 2008 59 1690 1697 10.1002/art.24092 19035419
6. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D, Ann Rheum Dis 2012 71 1524 1529 10.1136/annrheumdis-2011-200726 22425941
7. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature. Levy L, Fautrel B, Barnetche T, Schaeverbeke T, Clin Exp Rheumatol 2008 26 673 679 18799105
8. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Van Doornum S, Brand C, King B, Sundararajan V, Arthritis Rheum 2006 54 2061 2068 10.1002/art.21932 16802340
9. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE, Arthritis Rheum 2005 52 402 411 10.1002/art.20853 15693010
10. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. Smolina K, Wright FL, Rayner M, Goldacre MJ, BMJ 2012 344 8059 10.1136/bmj.d8059 22279113
11. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Krishnan E, Lingala VB, Singh G, Circulation 2004 110 1774 1779 10.1161/01.CIR.0000142864. 83780.81 15381644
12. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden. Bergstrom U, Jacobsson LT, Turesson C, Rheumatology (Oxford) 2009 48 1600 1605 10.1093/rheumatology/kep301 19858122
13. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A, Arthritis Rheum 2001 44 2737 2745 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-# 11762933
14. Antirheumatic drug use and the risk of acute myocardial infarction. Suissa S, Bernatsky S, Hudson M, Arthritis Rheum 2006 55 531 536 10.1002/art.22094 16874796
15. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Avina-Zubieta JA, Abrahamowicz M, De Vera MA, Choi HK, Sayre EC, Rahman MM, Sylvestre MP, Wynant W, Esdaile JM, Lacaille D, Rheumatology (Oxford) 2013 52 68 75 10.1093/rheumatology/kes353 23192907
16. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg JD, Ann Rheum Dis 2010 69 1920 1925 10.1136/ard.2009. 122226 20444756
17. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Stürmer T, Arthritis Rheum 2008 59 1097 1104 10.1002/art.23911 18668605
18. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Peters MJ, Van Sijl AM, Voskuyl AE, Sattar N, Smulders YM, Nurmohamed MT, Curr Pharm Des 2012 18 1502 1511 10.2174/138161212799504786 22364134
19. Increased cardiovascular risk factors in different rheumatic diseases compared with the general population. Meek IL, Picavet HS, Vonkeman HE, Verschuren WM, van de Laar MA, Rheumatology (Oxford) 2013 52 210 216 10.1093/rheumatology/kes194 22847678
20. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. van Gestel AM, Haagsma CJ, van Riel PL, Arthritis Rheum 1998 41 1845 1850 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0. CO;2-K 9778226
21. Cardiac failure and sudden death in the Framingham Study. Kannel WB, Plehn JF, Cupples LA, Am Heart J 1988 115 869 875 10.1016/0002-8703(88)90891-5 3354416
22. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Assous N, Touze E, Meune C, Kahan A, Allanore Y, Joint Bone Spine 2007 74 66 72 10.1016/j.jbspin.2006.10.001 17174586
23. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, Schneeweiss S, Arthritis Rheum 2006 54 3790 3798 10.1002/art.22255 17136752
24. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Peters MJ, Van Halm V, Voskuyl AE, Smulders YM, Boers M, Lems WF, Visser M, Stehouwer CD, Dekker JM, Nijpels G, Heine R, Dijkmans BA, Nurmohamed MT, Arthritis Rheum 2009 61 1571 1579 10.1002/art.24836 19877093
25. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, Alfreddson L, Askling J, J Intern Med 2010 268 578 585 10.1111/j.1365-2796.2010. 02260.x 20698926
26. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Ward MM, Arthritis Rheum 2001 44 1467 1469 10.1002/1529-0131(200106)44:6<1467::AID-ART243>3.0.CO;2-6 11407710
27. Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing. Ward MM, Arthritis Rheum 2008 59 1687 1689 10.1002/art.24170 19035434
28. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Libby P, Am J Med 2008 121 21 S31 10.1016/j.amjmed.2008.06.014 18926166
29. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Sattar N, McCarey DW, Capell H, McInnes IB, Circulation 2003 108 2957 2963 10.1161/01.CIR.0000099844.31524.05 14676136
30. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW, Dijkmans BA, Allaart CF, Ann Rheum Dis 2011 70 1039 1046 10.1136/ard.2010.141234 21415052
31. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D, Lancet 2004 364 263 269 10.1016/S0140-6736(04)16676-2 15262104
32. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, van Riel P, Fransen J, van de Laar MA, Ann Rheum Dis 2012 71 845 850 10.1136/annrheumdis-2011-200274 22210852
33. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? O'Flaherty M, Buchan I, Capewell S, Heart 2013 99 159 162 10.1136/heartjnl-2012-302300 22962283
34. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: Three year results of the DREAM remission induction cohort. Vermeer M, Kuper HH, Moens HJ, Drossaers-Bakker KW, Van Der Bijl AE, Van Riel PL, van de Laar MA, Arthritis Care Res (Hoboken) 2013 65 8 1219 1226 10.1002/acr.21984 23436821
35. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT, Ann Rheum Dis 2010 69 325 331 10.1136/ard.2009.113696 19773290
36. Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysis. Bartels CM, Kind AJ, Thorpe CT, Everett CM, Cook RJ, McBride PE, Smith MA, Semin Arthritis Rheum 2012 42 9 16 10.1016/j.semarthrit.2012.01.005 22424813
37. Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Desai SS, Myles JD, Kaplan MJ, Arthritis Res Ther 2012 14 270 10.1186/ar4118 23237607